Agios Pharmaceuticals (NASDAQ: AGIO) announced that, following a successful pre-SNDA meeting with the U.S. Food and Drug Administration (FDA), the company is actively advancing the accelerated approval process for its candidate drug mitapivat for the treatment of sickle cell disease (SCD).

Agios Pharmaceuticals (NASDAQ: AGIO) announced that, following a successful pre-SNDA meeting with the U.S. Food and Drug Administration (FDA), the company is actively advancing the accelerated approval process for its candidate drug mitapivat for the treatment of sickle cell disease (SCD).

老虎证券2026/03/31 11:16

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This key meeting clarified a feasible pathway for seeking accelerated approval of Mitapivat in the United States, marking an important step forward for the drug in addressing this serious hematological disease. The company plans to submit a marketing application to the FDA as soon as possible based on existing clinical data.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Agios Pharmaceuticals (NASDAQ: AGIO) announced that, following a successful pre-SNDA meeting with the U.S. Food and Drug Administration (FDA), the company is actively advancing the accelerated approval process for its candidate drug mitapivat for the treatment of sickle cell disease (SCD).

You may also like

Crypto prices